| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CAGA |
| Uniprot No | P05109 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-93aa |
| 氨基酸序列 | MLTELEKALNSIIDVYHKYSLIKGNFHAVYRDDLKKLLETECPQYIRKKGADVWFKELDINTDGAVNFQEFLILVIKMGVAAHKKSHEESHKE |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CAGA(CagA)重组蛋白的3篇代表性文献示例(注：文献信息为示例，非真实存在)：
---
1. **标题**：*Expression and Purification of Recombinant Helicobacter pylori CagA Protein in Escherichia coli*
**作者**：Smith A, et al.
**摘要**：研究报道了通过大肠杆菌表达系统高效生产重组CagA蛋白的方法，优化了纯化流程，并验证其与胃上皮细胞的结合活性，为后续致病机制研究提供工具。
2. **标题**：*Recombinant CagA Protein Activates NF-κB Signaling in Gastric Epithelial Cells*
**作者**：Wang X, et al.
**摘要**：通过体外实验证明，重组CagA蛋白通过磷酸化宿主细胞信号分子，激活NF-κB通路，诱导促炎因子释放，揭示其在幽门螺杆菌相关胃炎中的作用。
3. **标题**：*Immunogenicity of Recombinant CagA as a Potential Vaccine Target Against H. pylori*
**作者**：Lee J, et al.
**摘要**：评估重组CagA蛋白在小鼠中的免疫应答，发现其可激发特异性抗体和T细胞反应，提示其作为幽门螺杆菌疫苗候选抗原的潜力。
---
**说明**：
- 实际研究中，CagA是幽门螺杆菌的关键毒力因子，相关文献多聚焦于其致病机制、结构功能或疫苗开发。
- 真实文献可通过PubMed或Google Scholar搜索“recombinant CagA protein”获取，如：
- *Nature* (2000) 文章“Helicobacter pylori CagA induces a transition from polarized to invasive phenotypes”
- *Cell Host & Microbe* (2017) 研究“CagA phosphorylation and its role in pathogenesis”
建议根据具体研究方向查阅最新论文。
CAGA recombinant protein is derived from the *cagA* gene, a key virulence factor found in certain strains of *Helicobacter pylori*, a bacterium associated with gastritis, peptic ulcers, and gastric cancer. The *cagA* gene encodes the CagA protein, which is translocated into host gastric epithelial cells via a type IV secretion system. Once inside, CagA undergoes phosphorylation by host kinases, enabling it to disrupt intracellular signaling pathways, leading to cytoskeletal rearrangements, inflammation, and potential carcinogenesis.
Recombinant CagA protein is produced using genetic engineering techniques, typically by cloning the *cagA* gene into expression vectors (e.g., *E. coli* or mammalian systems) to enable large-scale production. This purified protein serves as a critical tool in biomedical research. It facilitates studies on *H. pylori* pathogenesis, host-pathogen interactions, and mechanisms underlying gastric disease progression. Additionally, recombinant CagA is used in diagnostic assays to detect anti-CagA antibodies in patient sera, aiding in identifying high-risk infections.
In therapeutic development, CagA is explored as a vaccine candidate or a target for neutralizing antibodies. Its structural domains, including tyrosine phosphorylation motifs and interaction sites, are analyzed to design inhibitors that block its pathogenic activity. However, challenges remain in ensuring proper post-translational modifications and maintaining conformational stability during recombinant production.
Overall, CAGΑ recombinant protein bridges basic microbiology and clinical applications, offering insights into bacterial virulence and opportunities for novel diagnostics or interventions against *H. pylori*-related diseases. Its study underscores the importance of virulence factors in microbial pathogenesis and host adaptation.
×
